| Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia (NCT00337662) | Eli Lilly and Company | 2006-05-01 |
| A Study Using Rapid Acting Intramuscular Olanzapine in Agitated Patients With Schizophrenia (NCT00316238) | Eli Lilly and Company | 2006-04-01 |
| Efficacy Study of Gemcitabine-Paclitaxel to Treat Metastatic Breast Cancer (NCT00316199) | Eli Lilly and Company | 2006-04-01 |
| Study of Human Insulin Inhalation Powder in Patients With Type 2 Diabetes (NCT00325364) | Eli Lilly and Company | 2006-04-01 |
| A Study of IMC-A12 Every 2 Weeks in Patients With Tumors Who No Longer Respond to Treatment or No Treatment is Available (NCT00785941) | Eli Lilly and Company | 2006-04-01 |
| Efficacy of Atomoxetine on Psychosocial Function of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) (NCT00320528) | Eli Lilly and Company | 2006-04-01 |
| Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia (NCT00320489) | Eli Lilly and Company | 2006-04-01 |
| Maintenance of Effect of Duloxetine in Patients With Diabetic Peripheral Neuropathic Pain (DPNP) (NCT00322621) | Eli Lilly and Company | 2006-04-01 |
| A Multi-Site Study to Evaluate the Safety and Effect of Study Drug on Participants With Rheumatoid Arthritis (NCT00308282) | Eli Lilly and Company | 2006-03-28 |
| Observational Study of Pergolide Mesylate and Cardiac Valvulopathy (NCT00311532) | Eli Lilly and Company | 2006-03-01 |
| An Open Label Study of Oral Enzastaurin in Participants With Cancer (NCT00309140) | Eli Lilly and Company | 2006-03-01 |
| Comparing the Effect of Under the Tongue Olanzapine Versus Swallowed Olanzapine on Body Mass Index (A Ratio of Weight to Height) (NCT00303602) | Eli Lilly and Company | 2006-03-01 |
| First Line Chemotherapy Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (NCT00308750) | Eli Lilly and Company | 2006-03-01 |
| Study of IMC-1121B in Patients With Advanced Solid Tumors Not Responding To Standard Therapy (NCT00786383) | Eli Lilly and Company | 2006-02-01 |
| Enzastaurin Versus Lomustine in Glioblastoma (NCT00295815) | Eli Lilly and Company | 2006-01-01 |
| A Dose-Escalation Study in Participants With Recurrent Malignant Glioma (NCT01682187) | Eli Lilly and Company | 2005-12-15 |
| Concurrent Pemetrexed, Cisplatin and Radiation Therapy in Patients With Stage IIIA/B Non Small Cell Lung Cancer (NCT00529100) | Eli Lilly and Company | 2005-12-01 |
| Phase 2 Study of Gemcitabine or Gemcitabine + Enzastaurin in Participants With Advanced or Metastatic Pancreatic Cancer (NCT00267020) | Eli Lilly and Company | 2005-12-01 |
| Tolerability of Switching to Duloxetine for the Management of Diabetic Nerve Pain (NCT00266643) | Eli Lilly and Company | 2005-12-01 |
| Study the Safety and Effectiveness of Tadalafil on High Blood Pressure in the Blood Vessel Going From the Heart to the Lungs (NCT00549302) | Eli Lilly and Company | 2005-12-01 |
| Long-Term Growth and Skeletal Effects of Early Growth Hormone Treatment in Turner Syndrome (NCT00266656) | Eli Lilly and Company | 2005-12-01 |
| The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV) (NCT00279201) | Eli Lilly and Company | 2005-12-01 |
| Feasibility Study of Pemetrexed in Combination With Cisplatin or Carboplatin as Adjuvant Treatment of Non-Small Cell Lung Cancer (NCT00269152) | Eli Lilly and Company | 2005-12-01 |
| Efficacy Study of LY2422347 to Treat Insomnia (NCT00259311) | Eli Lilly and Company | 2005-11-01 |
| A Safety and Pharmacokinetics Study in Participants With Rheumatoid Arthritis (NCT00380744) | Eli Lilly and Company | 2005-11-01 |
| Evaluation of the Effects of Teriparatide on Skeleton Images in Postmenopausal Women With Osteoporosis (NCT00259298) | Eli Lilly and Company | 2005-11-01 |
| Pemetrexed and Cisplatin Treatment Before Surgery in Non Small Cell Lung Cancer (NCT00259285) | Eli Lilly and Company | 2005-11-01 |
| Efficacy and Safety of Olanzapine in the Extended Treatment for Manic or Mixed Episode of Bipolar I Disorder (NCT00266630) | Eli Lilly and Company | 2005-11-01 |
| Validation of Multidimensional Assessment of THYmic States (MATHYS): A Study in a Population of Bipolar Patients Treated With Olanzapine (NCT00259272) | Eli Lilly and Company | 2005-11-01 |
| Hemodynamic and Perfusion Response to Drotrecogin Alfa (Activated) in Patients With Septic Shock (NCT00279214) | Eli Lilly and Company | 2005-11-01 |
| Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma (NCT00251550) | Eli Lilly and Company | 2005-10-01 |
| To Determine How Effective Duloxetine is in Treating Women 65 Years and Older With Symptoms of Stress Urinary Incontinence, or With a Combination of Stress Urinary Incontinence and Urge Urinary Incontinence Symptoms (NCT00244296) | Eli Lilly and Company | 2005-10-01 |
| A Study of IMC-A12 in Participants With Tumors Who No Longer Respond to Treatment or For Whom No Treatment is Available (NCT00785538) | Eli Lilly and Company | 2005-10-01 |
| Effects of LY450139 Dihydrate on Subjects With Mild to Moderate Alzheimer's Disease (NCT00244322) | Eli Lilly and Company | 2005-10-01 |
| A Phase II Study of Cetuximab Plus Irinotecan in Patients With EGFR-detectable Metastatic Colorectal Carcinoma (NCT00362102) | Eli Lilly and Company | 2005-10-01 |
| Tadalafil in Subjects With Mild to Moderate Hypertension (NCT00157326) | Eli Lilly and Company | 2005-09-01 |
| An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma (NCT00207116) | Eli Lilly and Company | 2005-09-01 |
| Complaints Associated With Use of Pre-Filled Pen B With Type 2 Diabetics on Twice-Daily Insulin (NCT00231725) | Eli Lilly and Company | 2005-09-01 |
| Phase III Study of Two Different Schedules (Weekly and Tri-weekly) of Combination of Gemcitabine and Two Taxanes in MBC (NCT00236899) | Eli Lilly and Company | 2005-09-01 |
| Duloxetine Versus Placebo in the Treatment of FMS (NCT00233025) | Eli Lilly and Company | 2005-09-01 |
| Neuropsychological Functioning in Children With Attention-Deficit/Hyperactivity Disorder. (NCT00216918) | Eli Lilly and Company | 2005-09-01 |
| Teriparatide and Strontium Ranelate Head-To-Head Comparison Trial (NCT00239629) | Eli Lilly and Company | 2005-09-01 |
| Preoperative Treatment of Breast Cancer With Two Different Sequential Treatment Regimens (NCT00149214) | Eli Lilly and Company | 2005-09-01 |
| Study of Cetuximab in Combination With Tarceva in Patients With Solid Tumors (NCT00207077) | Eli Lilly and Company | 2005-08-01 |
| Head and Neck Cancer Registry (LORHAN) (NCT01080313) | Eli Lilly and Company | 2005-08-01 |
| PHIRST-1: Tadalafil in the Treatment of Pulmonary Arterial Hypertension (NCT00125918) | Eli Lilly and Company | 2005-08-01 |
| Safety and Efficacy of Inhaled Insulin in Patients With Diabetes and Asthma or COPD (NCT00157339) | Eli Lilly and Company | 2005-08-01 |
| Enzastaurin for Patients With Metastatic Colorectal Cancer (NCT00192114) | Eli Lilly and Company | 2005-08-01 |
| Study of Erbitux™ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors (NCT00110357) | Eli Lilly and Company | 2005-08-01 |
| Study of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes (NCT00127634) | Eli Lilly and Company | 2005-07-01 |
| Trial of Olanzapine in Patients With Manic or Mixed Episode of Bipolar I Disorder (NCT00129220) | Eli Lilly and Company | 2005-07-01 |
| A Study of Duloxetine in the Treatment of Fibromyalgia (NCT00125892) | Eli Lilly and Company | 2005-07-01 |
| A Study in People With Abnormal Fat Levels in the Blood (NCT00116519) | Eli Lilly and Company | 2005-07-01 |
| Trial of Pemetrexed and Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal Cancer (NCT00489359) | Eli Lilly and Company | 2005-07-01 |
| A Study in People With High Cholesterol (NCT00133380) | Eli Lilly and Company | 2005-07-01 |
| A Study of Pemetrexed and Cyclophosphamide Given Every 21 Days in Advanced Breast Cancer Patients (NCT00190671) | Eli Lilly and Company | 2005-06-01 |
| Placebo-Controlled Study of Atomoxetine Hydrochloride in the Treatment of Adults With ADHD and Comorbid Social Anxiety Disorder (NCT00190879) | Eli Lilly and Company | 2005-06-01 |
| Study of Duloxetine Versus Placebo in the Treatment of Fibromyalgia Syndrome (NCT00190866) | Eli Lilly and Company | 2005-06-01 |
| Olanzapine Treated Adolescents With Schizophrenia or Bipolar I Disorder (NCT00113594) | Eli Lilly and Company | 2005-06-01 |
| A Study of Visual Effects of Erectile Dysfunction Medications Dosed Daily for Six Months (NCT00333281) | Eli Lilly and Company | 2005-06-01 |
| Gemcitabine Monotherapy for Metastatic Breast Cancer After Anthracycline and Taxane Regimen (NCT00191269) | Eli Lilly and Company | 2005-06-01 |
| Study of Pemetrexed in the Treatment of Patients With Ovarian Cancer Who Have Failed Prior Platinum-Based Chemotherapy (NCT00109096) | Eli Lilly and Company | 2005-06-01 |
| Molecular Profiling in Lung Cancer Patients (NCT00191308) | Eli Lilly and Company | 2005-05-01 |
| A Randomized Double Blind Study Evaluating Duloxetine in Outpatients With MDD and Pain (NCT00191919) | Eli Lilly and Company | 2005-05-01 |
| Long-Term Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder (AD/HD) (NCT00191386) | Eli Lilly and Company | 2005-05-01 |
| Efficacy and Safety of Atomoxetine in Children With Recent Diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD) (NCT00191945) | Eli Lilly and Company | 2005-05-01 |
| Comparison of Atomoxetine and Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and/or Reading Disorder (RD) (NCT00191906) | Eli Lilly and Company | 2005-04-01 |
| A Comparison of Duloxetine Hydrochloride, Marketed Comparator, and Placebo in the Treatment of Generalized Anxiety Disorder (NCT00122837) | Eli Lilly and Company | 2005-04-01 |
| Study of Atomoxetine in Children With ADHD to Assess Symptomatic and Functional Outcomes (NCT00191633) | Eli Lilly and Company | 2005-04-01 |
| Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer (NCT00106002) | Eli Lilly and Company | 2005-04-01 |
| Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder (NCT00105989) | Eli Lilly and Company | 2005-03-01 |
| Local Registration Trial in China Humalog Mix 50 (NCT00191581) | Eli Lilly and Company | 2005-03-01 |
| Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer. (NCT00105092) | Eli Lilly and Company | 2005-03-01 |
| Open-Label Duloxetine Extension Phase in Patients Who Have Completed Previous Duloxetine Trials (NCT00191594) | Eli Lilly and Company | 2005-03-01 |
| A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer (NCT00162318) | Eli Lilly and Company | 2005-03-01 |
| Pemetrexed and Best Supportive Care Versus Placebo and Best Supportive Care in Non-Small Cell Lung Cancer (NSCLC) (NCT00102804) | Eli Lilly and Company | 2005-03-01 |
| Gemcitabine Combinations in Metastatic Breast Cancer (MBC), 1st Line (NCT00191854) | Eli Lilly and Company | 2005-03-01 |
| Atomoxetine vs Placebo in the Treatment of ADHD in Swedish Children and Adolescents (NCT00191542) | Eli Lilly and Company | 2005-03-01 |
| A Trial for Patients With Advanced/Recurrent Cervical Cancer (NCT00190983) | Eli Lilly and Company | 2005-02-01 |
| Clinical Trial of Teriparatide in Japan (NCT00191867) | Eli Lilly and Company | 2005-02-01 |
| Atomoxetine Versus Placebo in Children With Attention Deficit/Hyperactivity Disorder (ADHD) (NCT00191295) | Eli Lilly and Company | 2005-02-01 |
| Biomechanical and Electrophysiological Effects of Duloxetine in the Treatment of Women With Urinary Stress Incontinence (NCT00190853) | Eli Lilly and Company | 2005-01-01 |
| Gemcitabine and Pemetrexed in Primary Unknown Adenocarcinoma (NCT00191503) | Eli Lilly and Company | 2005-01-01 |
| A Study of Pemetrexed in the Treatment of Patients With Advanced Metastatic Cancer of the Liver (NCT00191412) | Eli Lilly and Company | 2005-01-01 |
| Study of IMC-1121B in Patients With Tumors That Have Not Responded to Therapy (NCT00793975) | Eli Lilly and Company | 2005-01-01 |
| Study of Gemcitabine/Platinum +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer (NCT00112346) | Eli Lilly and Company | 2005-01-01 |
| Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer (NCT00095199) | Eli Lilly and Company | 2005-01-01 |
| Duloxetine Compared With Placebo in the Prevention of Relapse in Generalized Anxiety Disorder (NCT00122863) | Eli Lilly and Company | 2005-01-01 |
| Effects of Teriparatide on Distal Radius Fracture Healing (NCT00190944) | Eli Lilly and Company | 2004-12-01 |
| Gemcitabine and Platinol Followed by Pemetrexed and Gemcitabine in Patients With Advanced or Metastatic Bladder Cancer (NCT00101842) | Eli Lilly and Company | 2004-12-01 |
| Gemcitabine in Ovarian Cancer (NCT00191334) | Eli Lilly and Company | 2004-12-01 |
| Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer (NCT00112294) | Eli Lilly and Company | 2004-12-01 |
| A Study for Patients With Secondary Progressive Multiple Sclerosis (NCT00869726) | Eli Lilly and Company | 2004-12-01 |
| Comparison of LY686017 With a Marketed Drug in the Treatment of Social Anxiety Disorder (NCT00191022) | Eli Lilly and Company | 2004-12-01 |
| A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma (NCT00082212) | Eli Lilly and Company | 2004-11-01 |
| Comparing Intensive and Standard Training for Human Insulin Inhalation Powder (HIIP) (NCT00099515) | Eli Lilly and Company | 2004-11-01 |
| Study of IMC-11F8 in Patients With Tumors Who Have Not Responded to Standard Therapy (NCT00801177) | Eli Lilly and Company | 2004-11-01 |
| A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention (NCT00097591) | Eli Lilly and Company | 2004-11-01 |
| Trial of Carboplatin/Paclitaxel/Cetuximab in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) (NCT00097227) | Eli Lilly and Company | 2004-11-01 |
| A Trial of Erbitux for Recurrent and Metastatic Mucinous Gastrointestinal Adenocarcinoma Involving the Peritoneal Surfaces (NCT00162110) | Eli Lilly and Company | 2004-11-01 |